Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If/when we finally see the balance sheet my bet is it will be more green than red.
I know WNBD says they don't plan the release dates of their PR's, but this could conveniently set up a higher base to launch from when the national retailer is anounced...
Competitors in the area will have to follow suit... it's going to grow like a wild fire.
Just imagine this originating in FL:
WNBD too?
Yes I am most certainly an optimist, you're right about that. As for your concern about something falling off the hemopurifier, do you mean the potential for pathogens that it has captured to fall off and recirculate into the blood? The complete volume of blood in an average sized person circulates in less than a minute at rest, so whether a pathogen does make it back into the blood stream or if it's not captured on the first pass through the cartridge it's just a matter of minutes for it to make another pass, no?
Perhaps this is why their treatment tims range from 30 minutes to a few hours. I don't know all the details about the device, but if the hemopruifier becomes saturated (as may be the case with the first treatment only?) a second cartridge could theoretically be used.
All that being said, I wouldn't be surprised if there was a hemotologist reading this board... Is there a doctor in the house?
Good job, I look forward to hearing their oppinions. I work at a biotech company - it's not a medical device company, but I work with several former MIT professors and a Nobel Prize winner (look up Tonegawa on Google) at a startup. I've tossed the idea of the hemopurifier around them and they're all very intrigued and interested.
None of them have indicated that there's any reason it shouldn't work. The only concern they've raised has been that there may be resistance from the big pharmas (and therefore the FDA) because it might work TOO well, but if this is the case it can't be ignored forever, IMO.
This is old, but appropriate...
http://paulbattaglia.blogspot.com/2008/03/ugh.html
Just an example of someone learning where their money should be.
Haha nice, what do you suppose he's shooting at?
Great Cougar, thanks for checking in. It could be anamazing week.
Hey Soapy, thanks for posting that link - very enlightening.
Also, Go Sox.
-M2C from Fenway
There's definitely a lot of painting going on in the show.
Haha unfortunately I don't either, just aware of the schedule... :)
Color Splash starting in few minutes...
Has anyone heard about their order from Pearson at all? I placed an order ,got a receipt, etc, haven't heard or seen anything since.
Look for green today. The next run could start soon and last through the end of April.
Just M2C
Aethlon Medical Inc. has added a news release to its Investor Relations website.
Title: The Aethlon Hemopurifier(R) to Test Against the Partially Reconstructed 1918 Influenza Virus
Date: 4/10/2008 10:49:00 AM
For a complete listing of our news releases, please click here
SAN DIEGO--(BUSINESS WIRE)--April 10, 2008--Aethlon Medical, Inc.
(OTCBB:AEMD) disclosed today that it has initiated studies to test the
in vitro effectiveness of the Aethlon Hemopurifier(R) to capture a
partially reconstructed version of the Spanish Flu of 1918, a viral
pandemic outbreak that killed approximately 40-50 million people
during a 25-month time span. The reconstructed 1918 influenza used in
the Hemopurifier(R) studies is a recombinant virus that has two genes
(the HA and NA) from the 1918 strain of influenza along with six genes
from the Texas 91 influenza strain. The resulting research virus is
known as 1918 HA/NA:TX/36/91.
The 1918 HA/NA:TX/36/91 studies are designed to evaluate the
potential of the Hemopurifier(R) to treat future outbreaks of pandemic
influenza, and to further demonstrate the broad-spectrum effectiveness
of the Hemopurifier(R) to capture viral pathogens. The studies will be
conducted at a global contract research organization that previously
collaborated with Aethlon Medical on pre-clinical testing of the
Hemopurifier(R) against the highly fatal H5N1 Avian Flu Virus (bird
flu). In those studies, the Hemopurifier(R) proved effective in
removing up to 99.4 percent of infectious H5N1 from cell culture
fluids during a six-hour testing period.
The U.S. Department of Health and Human Services (HHS) has
recently mandated that therapies able to demonstrate broad-spectrum
effectiveness against multiple pathogens, including pandemic
influenza, be the focal point of government programs that support the
commercialization of candidate countermeasures against bioterror and
pandemic threats. Aethlon Medical considers the Hemopurifier(R) to be
the leading broad-spectrum candidate as evidenced by its breadth of
pre-clinical data and human treatment experience. Data resulting from
the 1918 HA/NA:TX/36/91 study and other clinical programs will be
included in a forthcoming submission to HHS and the recently
established Biomedical Research and Development Authority (BARDA) to
advance the commercialization of the Hemopurifier(R) as a
broad-spectrum countermeasure against bioterror and pandemic threats.
About the Spanish Flu of 1918
The Spanish Flu of 1918 lasted from March 1918 to June 1920 (25
months) and is estimated to have killed 40-50 million people
worldwide. As a comparison, approximately 25 million AIDS related
deaths have occurred during the first 25 years of the disease. In
contrast to most influenza outbreaks, the primary victims of the
Spanish Flu of 1918 were healthy young adults. Researchers believe the
virulence associated with the 1918 virus was triggered by an
overreaction of the immune system, known as a cytokine storm. As a
result, juveniles and elderly with weaker immune systems had a lower
incidence of morbidity and mortality. The fatality rate of those
infected with the Spanish Flu of 1918 is estimated at 2.5-5 percent.
Scientists have reported the 1918 Spanish flu virus was initially a
bird flu virus that evolved to be efficiently passed in human-to-human
transmissions. Alarmingly, the greater than 50 percent human fatality
rate of today's H5N1 bird flu virus is also associated with the
cytokine storm. Justifiably, researchers believe further studies of
the reconstructed 1918 influenza virus may provide scientific insight
necessary to advance therapeutic strategies able to address future
pandemic influenza outbreaks.
About Aethlon Medical
Aethlon Medical is the developer of the Hemopurifier(R), a
first-in-class medical device designed to treat infectious disease.
The Hemopurifier(R) provides real-time therapeutic filtration of
infectious viruses and immunosuppressive particles, and is positioned
to address the treatment of drug and vaccine resistant viruses. The
device also holds promise in cancer care, as research studies have
verified the Hemopurifier(R) able to capture immunosuppressive
particles that are secreted by tumors. The Hemopurifier(R) is targeted
for use a stand-alone therapeutic, and as an adjunct treatment to
enhance clinical benefit of established and candidate therapies.
Pre-clinical studies conducted by researchers representing leading
government and non-government health organizations both in the United
States and abroad have documented the effectiveness of the
Hemopurifier(R) in capturing pandemic threats, including H5N1 Avian
Influenza (bird flu), and Dengue Hemorrhagic Fever (DHF) from
circulation. Studies are also being conducted to support the use of
the Hemopurifier(R) as a broad-spectrum treatment countermeasure
against bioterror threats, including Smallpox, and Ebola, Marburg, and
Lassa hemorrhagic fever. Regulatory and commercialization initiatives
in the United States are presently focused on bioterror threats, while
international initiatives are directed toward naturally evolving
pandemic threats, and chronic infectious disease conditions including
the Human Immunodeficiency Virus (HIV) and Hepatitis-C (HCV). Aethlon
has previously demonstrated safety of the Hemopurifier(R) in a
24-treatment human study at the Apollo Hospital in Delhi, India, and
is currently conducting further human studies at the Fortis Hospital,
also located in Delhi. The Company has submitted an Investigational
Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA)
related to advancing the Hemopurifier(R) as a broad-spectrum treatment
countermeasure against category "A" bioterror threats. Additional
information regarding Aethlon Medical and its Hemopurifier(R)
technology is available online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and
involve risks and uncertainties. Such forward-looking statements
involve assumptions, known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or
achievements of Aethlon Medical, Inc to be materially different from
any future results, performance, or achievements expressed or implied
by the forward-looking statements. Such potential risks and
uncertainties include, without limitation, the Company's ability to
raise capital when needed, the Company's ability to complete the
development of its planned products, the ability of the Company to
obtain FDA and other regulatory approvals permitting the sale of its
products, the Company's ability to manufacture its products and
provide its services, the impact of government regulations, patent
protection on the Company's proprietary technology, product liability
exposure, uncertainty of market acceptance, competition, technological
change, and other risk factors. In such instances, actual results
could differ materially as a result of a variety of factors, including
the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and
Exchange Commission filings.
CONTACT: Aethlon Medical, Inc.
Cynthia Bond, Director of Investor Relations
858.735.0069
cbond@aethlonmedical.com
or
Jeff Richardson, Senior Director, Communications
858.459.7800 x302
jrichardson@aethlonmedical.com
SOURCE: Aethlon Medical, Inc.
I don't want WNBD to be wal mart's private label, I think many go to Wal mart for cheap stuff but think of the wal mart brands themselves as being too cheap. WNBD will be right there next to Wal MOxibrite on the shelf...
Oh, and 24's back up.
What scanners do you use?
Aethlon Medical Inc. has added a news release to its Investor Relations website.
Title: Aethlon Medical Announces West Nile Research Collaboration
Date: 4/2/2008 10:05:00 AM
For a complete listing of our news releases, please click here
SAN DIEGO--(BUSINESS WIRE)--April 2, 2008--Aethlon Medical, Inc.
(OTCBB:AEMD) announced today that it will initiate studies to test the
in vitro effectiveness of the Aethlon Hemopurifier(R) to capture West
Nile virus (WNV), an infectious disease presently untreatable with
antiviral drug and vaccine therapy. The studies are designed to
evaluate the potential of the Hemopurifier(R) to treat WNV, and to
further demonstrate the broad-spectrum effectiveness of the
Hemopurifier(R) to capture viral pathogens.
Therapies able to demonstrate broad-spectrum effectiveness against
multiple pathogens have recently been mandated by the U.S. Department
of Health and Human Services (HHS) to be the focal point of government
programs that support the commercialization of candidate
countermeasures against bioterror and pandemic threats. Aethlon
Medical considers the Hemopurifier(R) to be the leading broad-spectrum
candidate as evidenced by its breadth of pre-clinical data and human
treatment experience. Data resulting from the WNV study and other
clinical programs will be included in a forthcoming submission to HHS
and the newly established Biomedical Research and Development
Authority (BARDA) to advance the commercialization of the
Hemopurifier(R) as a broad-spectrum countermeasure against bioterror
and pandemic threats.
The WNV studies will be conducted at the Battelle Biomedical
Research Center, a global research organization who previously
collaborated with Aethlon Medical on pre-clinical testing of the
Hemopurifier(R) against the highly fatal H5N1 Avian Flu Virus (bird
flu). In those studies, the Hemopurifier(R) proved effective in
removing up to 99.4% of infectious H5N1 from cell culture fluids
during a six-hour testing periods.
WNV first appeared in the Western hemisphere in 1999, and is
believed to have entered via an infected bird or mosquito, the primary
vector for human infection. Incidence of infection within the U.S. has
since increased with approximately 3,600 cases reported in 2007, 33
percent of which were the more severe neuro-invasive forms, and these
resulted in 121 fatalities. It is further believed that there is a
significant underreporting of the number of actual cases. The cost of
West Nile related health care in the U.S. exceeded $200 million in the
2002 alone.
About Battelle Biomedical Research Center
Battelle is the world's largest non-profit independent research
and development organization, providing innovative solutions to the
world's most pressing needs through its four global businesses:
laboratory management, national security, energy technology and health
and life sciences. It advances scientific discovery and application by
conducting $4 billion in global R&D annually through contract
research, laboratory management and technology commercialization.
Headquartered in Columbus, Ohio, Battelle oversees 20,400 employees in
more than 120 locations worldwide, including seven national
laboratories that Battelle manages or co-manages for the U.S.
Department of Energy and the U.S. Department of Homeland Security.
Battelle is also one of the nation's leading charitable trusts
focusing on societal and economic impact and actively supporting and
promoting science and math education. For more information, visit
www.battelle.org.
About Aethlon Medical
Aethlon Medical is the developer of the Hemopurifier(R), a
first-in-class medical device designed to treat infectious disease.
The Hemopurifier(R) provides real-time therapeutic filtration of
infectious viruses and immunosuppressive particles, and is positioned
to address the treatment of drug and vaccine resistant viruses. The
device also holds promise in cancer care, as research studies have
verified the Hemopurifier(R) able to capture immunosuppressive
particles that are secreted by tumors. The Hemopurifier(R) is targeted
for use a stand-alone therapeutic, and as an adjunct treatment to
enhance clinical benefit of established and candidate therapies.
Pre-clinical studies conducted by researchers representing leading
government and non-government health organizations both in the United
States and abroad have documented the effectiveness of the
Hemopurifier(R) in capturing pandemic threats, including H5N1 Avian
Influenza (bird flu), and Dengue Hemorrhagic Fever (DHF) from
circulation. Studies are also being conducted to support the use of
the Hemopurifier(R) as a broad-spectrum treatment countermeasure
against bioterror threats, including Smallpox, and Ebola, Marburg, and
Lassa hemorrhagic fever. Regulatory and commercialization initiatives
in the United States are presently focused on bioterror threats, while
international initiatives are directed toward naturally evolving
pandemic threats, and chronic infectious disease conditions including
the Human Immunodeficiency Virus (HIV) and Hepatitis-C (HCV). Aethlon
has previously demonstrated safety of the Hemopurifier(R) in a
24-treatment human study at the Apollo Hospital in Delhi, India, and
is currently conducting further human studies at the Fortis Hospital,
also located in Delhi. The Company has submitted an Investigational
Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA)
related to advancing the Hemopurifier(R) as a broad-spectrum treatment
countermeasure against category "A" bioterror threats. Additional
information regarding Aethlon Medical and its Hemopurifier(R)
technology is available online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and
involve risks and uncertainties. Such forward-looking statements
involve assumptions, known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or
achievements of Aethlon Medical, Inc to be materially different from
any future results, performance, or achievements expressed or implied
by the forward-looking statements. Such potential risks and
uncertainties include, without limitation, the Company's ability to
raise capital when needed, the Company's ability to complete the
development of its planned products, the ability of the Company to
obtain FDA and other regulatory approvals permitting the sale of its
products, the Company's ability to manufacture its products and
provide its services, the impact of government regulations, patent
protection on the Company's proprietary technology, product liability
exposure, uncertainty of market acceptance, competition, technological
change, and other risk factors. In such instances, actual results
could differ materially as a result of a variety of factors, including
the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and
Exchange Commission filings.
CONTACT: Aethlon Medical, Inc.
Cynthia Bond
Director of Investor Relations
858.735.0069
cbond@aethlonmedical.com
Jeff Richardson
Senior Director, Communications
858.459.7800 x302
jrichardson@aethlonmedical.com
SOURCE: Aethlon Medical, Inc.
Thursday, Mar. 27 2008
Purio to Attend Water Quality Association Show in Las Vegas March 27-29
BLAINE, WA, Mar 27, 2008 (MARKET WIRE via COMTEX) -- Purio (OTCBB: PURO) is pleased to announce that it will have key personnel attend this world-class meeting of water industry businesses.
According to the Water Quality Association, WQA Aquatech USA is an international exhibition and conference on water technology which attracts multiple water industry groups including process, drinking water, ultrapure, and wastewater for residential, commercial, and industrial users.
"Purio Inc. regards this show as a perfect meeting place for our company and potential business partners in the water industry from the world over," says Earl Switenky, of Purio Inc. "A show of this caliber brings the best of the best under one roof. Our objective is to seek out companies which may be interested in and suitable for the establishment of strategic alliances through which to expand our market both domestically and internationally. While Purio is presently engaged in preliminary discussions with interested parties in India, China, Africa and the South Pacific, we feel that it's in the company's best interest to explore many avenues of market expansion."
About Purio Inc.
Purio owns proprietary water clarification technology suitable to a broad number of applications including the clarification of surface water, industrial process water and sewage. Purio intends to apply its technology initially to industrial and commercial applications to reclaim water and reduce the need for fresh water in such applications. Purio further intends to use its proprietary technology to produce potable water for commercial and residential use. Purio will commercialize its technology via a number of channels, namely licensing strategic partners to build and sell &/or operate units outside of North America, outright sale of their second generation (patent pending) units to end users and will build, own and operate on a fee for service basis their larger permanent installation units in North America.
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section21E of the United States Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Since the forward-looking statements relate to future developments, results or events, these statements are highly speculative and involve risks, uncertainties and assumptions that are difficult to assess. You should not construe any of these statements as a definitive or invariable expression of what will actually occur or result. Such forward-looking statements in this press release include, among others, the expectation and/or claim that:
Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, (i) Purio having enough funding to operate its business and retain ownership of its proprietary technology, Purio assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the Company believes that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance those beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the Company's periodic reports filed from time to time with the Securities and Exchange Commission and available at www.sec.gov.
Contact:
Shawn Van Damme
Investor Relations
1-877-512-1120
svd@puriowatertech.com
http://www.puriowatertech.comSOURCE: Purio Inc.
<a href="mailto:svd@puriowatertech.com" target="_blank"mailto:svd@puriowatertech.com</a
http://www.puriowatertech.comCopyright 2008 Market Wire, All rights reserved.
Anyone out there? This is one of the few stocks with infinite potential if they execute well.
great book about green companies:
http://www.amazon.com/Stirring-Up-Make-Money-World/dp/1401303447/ref=pd_bbs_sr_1?ie=UTF8&s=books&qid=1207074395&sr=8-1
Editorial Reviews
From Publishers Weekly
When a CEO—or in this case a CE-Yo—writes a book about the philosophical and environmental underpinnings of the company he founded, it is natural to expect an ego-driven text. But Hirshberg, founder of Stonyfield Farm, the organic yogurt maker, dilutes the ego with eco. After all, this is a book that presents management lessons gleaned from life on a farm: in one such lesson, a herd of hungry pigs attacks a mound of damaged plastic yogurt cups, devours the contents and teaches Hirschberg nature's idea of recycling. While there is some cultured finger-pointing at big-name competitors and other corporations for organic abstinence and environmental insensitivity, Hirshberg focuses on how Stonyfield succeeds in pursuing sustainability and profitability—not to mention valuable shelf space alongside giants like Kraft and Yoplait. But in addition to describing how his company addresses such tasks as negating its own carbon footprint or establishing a handshake with the consumer in lieu of advertising, Hirshberg shares stories of similar successes at other companies, including Whole Foods, Timberland and, more recently, at Zipcar. Hirshberg has produced a manual of use for managers at any size company with an earnest interest in learning how to save the world while enriching employees and shareholders. (Jan.)
Copyright © Reed Business Information, a division of Reed Elsevier Inc. All rights reserved.
Tom Vilsack, former governor of Iowa
"This is a must-read for every CEO of every company, big or small, who understands that a profitable company and a sustainable environment are mutually dependent."
Also, one that I like long term is Purio Environmental Water Source, Inc.: PURO(OTCBB) - water treatment and recycling... www.puriowatertech.com
It won't hurt my feelings if it doesn't make the cut, but check it out.
Hey Rocket, this is energy and mutual fund focused, but it's all about green investing:
Why 'Green' Investing Has Gained Focus [WSJ]
By JILIAN MINCER
June 21, 2007; Page D6
For Holly Isdale, managing director and head of wealth advisory at Lehman Brothers, global warming isn't a scientific theory -- it's an investment opportunity.
"It's not just tree huggers" who think about global warming, say Ms. Isdale. "There's money to be made, and people want to know how to make it."
This year, researchers at Citigroup Inc., Lehman Brothers Holdings Inc. and UBS AG have issued widely circulated reports on risks and opportunities for investors because of climate change. They argue that global warming can no longer be ignored as a factor in investing.
Researchers at these firms and others are identifying companies well-positioned for global warming, either because they are devising new technologies or because they are taking advantage of market changes.
Investment managers are introducing green mutual funds and exchange-traded funds, hoping to gain an investment edge. Investment strategists are advising bankers, brokers and clients to think about how climate change will affect their investments.
They are finding intense interest. Ms. Isdale says clients are asking about such things as potential investments, public policy, land conservation and environmentally beneficial philanthropy.
There are risks to investing with global warming in mind. Apart from individual stocks, few green investment products are available in the U.S., and most charge higher expenses than traditional mutual funds. Many of the companies involved in green technology are small, so they carry more investment risk; moreover, green technology is developing so quickly it is hard to predict which companies will eventually win.
Also, Americans could lose interest in more energy-efficient cars and other products if gasoline prices drop.
Despite the risks, green investment vehicles -- especially those in Europe -- are building successful track records, say green-investing advocates. New technologies and government mandates to cut emissions, especially overseas, are driving some investments. Scientific research, media coverage, changes in public policy, and even weather-related disasters such as Hurricane Katrina are driving awareness.
Citi Global has identified 85 companies in 23 countries and seven industry sectors that it thinks are well-positioned in the face of climate change. Food producer Archer-Daniels-Midland Co. has direct exposure to the global demand for ethanol. Honda Motor Co. was selected for its advanced diesel technology, and Toyota Motor Corp. for its hybrid engine technology. Citi Global also likes ACE Ltd. and Arch Capital Group Ltd., property and casualty insurers, because the serious hurricanes in recent years have led some large insurers and reinsurers to abandon some hurricane-prone regions of the U.S. As a result, there is an opportunity for some small insurers to move in.
Kurt Reiman, head of thematic research for UBS Wealth Management Research and co-author of its report "Beyond Whether," recommends that investors consider mutual funds, which would give them exposure to a number of companies, and allow professional managers to sort through the companies' changing fortunes. "It's a difficult investment, because a lot of emerging technology is in small-cap companies," which face more risks, he says.
Sustainable Asset Management of Zurich, which has $9 billion under management and advisement in Europe, has seven funds. Reto Ringger, founder and chief executive of the company, which developed the Dow Jones Sustainability Indexes, expects to offer some funds in the U.S. this fall. (Dow Jones & Co. publishes The Wall Street Journal.)
Calvert, one of the largest socially responsible mutual-fund firms in the U.S., last week introduced the Calvert Global Alternative Energy Fund, which invests in alternative-energy sectors such as solar, wind and hydroelectric power. The fund carries an annual expense ratio of 1.85%.
PowerShares WilderHill Clean Energy Portfolio, an exchange-traded fund, is a pick of Sacha Millstone, senior vice president for investments of the Millstone Evans Group at Raymond James & Associates in Colorado. ETFs resemble index funds but trade like stocks; this one has more than 40 stocks, with an expense-ratio cap of 0.6%. Some of its top holdings are in Echelon Corp., which provides networking technology, and Cree Inc., which makes semiconductors.
Ms. Millstone warns that investors need to determine their financial goals, risk tolerance and time frame before deciding how to allocate their portfolios.
How think is .03?
Hello GWMAN,
As far as I know they are already doing clinical studies in India (if I am incorrect, someone please let me know) so they may be beyond animal models altogether...
That being said, from my personal experience in behavioral pharmacology a company generally needs a different animal model for each disease state. I don't suspect they'd have to do much pharmacology and the device seems to have universal capture of just about anything infectious, but I do not know if the hemopurifier has to be modified at all to catpure the different types of foreign pathogens, i. e. if it can be used for anything and everything as-is or if there are different varieties for the different disease states.
Even acute animal models can take several months to complete, considering lead time on ordering the animals, protocol approval from local government and the Institutional Animal Care and Use Committee (IACUC), behavioral monitoring post procedure, etc. Animal models are not trivial, especially with non-rodents, and I suspect they would do any hemopurifier studies on monkeys or pigs, which I've heard they are especially useful for cardiac studies.. I work with several CNS models (schizophrenia, bipolar, depression, etc) which are of a much different nature than anything infectious, however, so my knowledge is still someone limited.
E-mail from Eric about the NYC advertising PR, originally posted on 3/18/08
Hello Mr. XXXX,
Thank you for your suggestion about HGTV Green Home. Yes, HGTV has many good touch points for Winning Brands products. A few of the positive aspects of beginning with Color Splash include its sponsorship by Home Depot for possible future tie-ins, “affordable” (in the sense that the word can be used for any form of TV advertising), flexibility for schedule changes, specific focus to painting (and thereby to the clean-ups that ensue), and other factors.
We approach things gradually to learn while the stakes are low and will evaluate how to optimize our connection to HGTV over time. Your feedback is a part of that process, so the time you have taken to share it is appreciated!
Sincerely,
Eric Lehner, CEO
Winning Brands Corporation
www.WinningBrands.ca
-----Original Message-----
- Hide quoted text -
Sent: March 18, 2008 12:32 PM
To: Eric Lehner
Subject: Re: Winning Brands Investor Correspondence
- Hide quoted text -
Portion of my e-mail to him
Congratulations to the company on this morning's PR about penetrating the NYC market via HGTV. Was there any discussion about advertising during the program titled "HGTV Green Home 2008"? It seems as though it is the number one show, and perhaps more importantly, the number one show people are interested in buying featured products from:
http://marketplace.hgtv.com/
And I can't help but imagine KIND sitting atop the washing machine in this HGTV Green Home 2008 marketplace link:
http://marketplace.hgtv.com/promo/green_home_2008
Perhaps there is a requirement for their featured products to have a third party green certification? I won't bother you anymore because I have little doubt you have, or are in the process of, exploring all possibilities. HGTV was a perfect move, in my opinion. I don't expect a response but would certainly welcome one at your convenience.
""""
It starts on a sunday, here is the show schedule:
http://www.hgtv.com/hgtv/shows_hclrs
First sunday show on the 6th is at 3:30 ET.
Speaking of hints from Eric... reposted e-mail about NYC Advertising:
E-mail from Eric about the morning PR
Hello Mr. XXXX,
Thank you for your suggestion about HGTV Green Home. Yes, HGTV has many good touch points for Winning Brands products. A few of the positive aspects of beginning with Color Splash include its sponsorship by Home Depot for possible future tie-ins, “affordable” (in the sense that the word can be used for any form of TV advertising), flexibility for schedule changes, specific focus to painting (and thereby to the clean-ups that ensue), and other factors.
We approach things gradually to learn while the stakes are low and will evaluate how to optimize our connection to HGTV over time. Your feedback is a part of that process, so the time you have taken to share it is appreciated!
Sincerely,
Eric Lehner, CEO
Winning Brands Corporation
www.WinningBrands.ca
It's been to almost 5 recently, many of us have doubled from here already. Trip zero's were obvious, but in my oppinion this is still a good time to get into WNBD. You might be telling your friends on this board to pass on big gains, short and long term.
I ordered another set of samples on behalf of my computer illiterate mother, who has also recently become a shareholder....
Notice the location of the Origin Scan.... coincidence?
Package Progress
Location Date Local Time Description
BUFFALO,
NY, US 03/25/2008 4:30 A.M. DEPARTURE SCAN
BUFFALO,
NY, US 03/24/2008 6:13 P.M. ORIGIN SCAN
US 03/24/2008 1:51 P.M. BILLING INFORMATION RECEIVED
Winning Brands Launches U.S. TV Advertising on FOX
Wednesday February 13, 11:53 am ET
Western New York Is the First U.S. TV Advertising Market for Winning Colours(R) Stain Remover
BARRIE, ON--(MARKET WIRE)--Feb 13, 2008 -- Winning Brands Corporation (Other OTC:WNBD.PK - News) (Frankfurt:WMU.F - News) (www.WinningBrands.ca) reports the expansion of its TV advertising to the United States for the first time. The new U.S. TV advertising campaign for Winning Colours® Stain Remover goes to air the week of February 25th, 2008. Western New York is the launch market, with FOX affiliate WUTV in Buffalo as the broadcast partner. The FOX affiliate is considered a regional super station because of the size of its local viewing audience and ranks only behind New York, Los Angeles and Chicago reaching over 3 million households and nearly 6,000,000 viewing adults. The initial Winning Colours® campaign will rotate through a number of popular programs and deliver approximately 2 Million viewer impressions.
Source: Winning Brands Corporation
(click to enlarge)
Winning Colours. Stain Remover's U.S. advertising commences on Buffalo, New York FOX affiliate WUTV to support Winning Brands' retailers and reinforce consumer awareness of the new brand. Commercials go to air starting the week of February 25, 2008
The large reach for the Winning Colours® Stain Remover TV advertising is made possible because, in addition to its normal distribution in New York State, the broadcaster's signal is supplied to cable systems in Southern Ontario. This dual market approach is uniquely suitable for Winning Colours® Stain Remover because it facilitates the product's emerging U.S. distribution while building on existing consumer awareness of Winning Colours® Stain Remover amongst the Canadian viewing audience.
Winning Brands Sales Management, Patricia Miles and Lorne Kelly, are ensuring that current and imminent retail partners for Winning Colours® Stain Remover will benefit from what is still considered by many to be the most powerful advertising medium in the world. "TV by far still delivers the most impactful experience in building brand awareness. Television advertising for Winning Colours® Stain Remover integrates the emerging popularity of the product and the stature of Winning Colours® first-class retail partners for mutual gain," says Patricia Miles, National Sales Manager for Winning Brands.
Commencement of Winning Brands' U.S. TV advertising represents the next level of development for a company whose brands are increasingly becoming favourites amongst consumers who discover them. Winning Colours® Stain Remover has been gaining fans steadily because of its gentleness to skin despite its powerful stain removing performance. Winning Brands' goal is for Winning Colours® Stain Remover to become North America's favourite stain removing product.
Winning Brands CEO Eric Lehner congratulates the FOX affiliate for putting forward an effective proposal to become the new marketing partner for the roll-out of the new environmentally gentle stain remover. "The efficiency, value for money and understanding of our goals was all there," says Lehner of the broadcaster and its representative Sue Simpson; "... so Winning Colours® Stain Remover is off to a good start with U.S. advertising." Lorne Kelly, Snr. VP of Winning Brands adds -- "We also look forward to working with News Corporation's Network Marketing group to service national accounts as they come on stream. That would provide a highly integrated marketing collaboration from the airwaves to the store shelf."
Winning Brands Corporation manufactures Winning Colours® Stain Remover for consumer and commercial use as an environmentally preferable alternative to traditional solvents. Production takes place at the Grand Rapids, Michigan facility of Surefil LLC. Winning Brands' full product range includes a variety of environmentally responsible alternative cleaning solutions, such as its non-toxic SMART(TM) Wet Cleaning Solutions alternative to Perchloroethylene used in Dry Cleaning, KIND(TM) Laundry Products and CLEAN1(TM) -- the first choice in outdoor cleaning. The company's mission is to replace hazardous chemicals in widespread use with safer alternatives. The initial focus is on cleaning products.
Certain statements in this news release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Winning Brands Corporation (the Company) to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; and (iii) competitive factors and developments beyond the Company's control. Winning Colors®, Winning Colours® is a Registered Trademark of Niagara Mist Marketing Ltd . KIND(TM) and CLEAN1(TM) are trademarks of Niagara Mist Marketing Ltd. SMART(TM) is a trademark of Solvent Free Solutions Inc.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=689679
Contact:
Information:
Winning Brands Corporation
Office Direct (705) 737-4062
11 Victoria Street, Suite 220A
Barrie, Ontario, Canada L4N 6T3
News@WinningBrands.ca
Me too... we'll keep them in business, we don't need all those new yorkers or the hundreds of thousands of people going to HD and Wal mart Cananda every week...
Wal Mart USA in our future?
Check out this time-lapse video of their stores opening across the US.... then imagine the WNBD products being in all of these and all of the HD's in the long term.
http://blog.kiwitobes.com/?p=51
That's what I'm saying... April 6th. I'm taking the under, though.
Is April 6th the over/under on the "April announcement"? I'll take under....
Winning Brands Launches New York City TV Advertising
Tuesday 03/18/2008 8:16 AM ET - Market Wire
Winning Brands Corporation (PINKSHEETS: WNBD) (FRANKFURT: WMU) www.WinningBrands.ca reports the expansion of its television advertising to New York City for the first time. HGTV http://www.hgtv.com is a popular source of home improvement programming in New York City, the most densely populated television viewing market in America -- and is one of the most popular broadcasters in the USA. Winning Brands' versatile stain removing product, Winning Colours(R) Stain Remover, will air commercials in the network's program "Color Splash" staring David Bromstad and Danielle Hirsch, to its New York City audience through Time Warner cable. http://www.hgtv.com/hgtv/shows_hclrs
The commercials will begin on Sunday, April 6th and introduce New Yorkers to Winning Colours Stain Remover's retail partners there as a regular feature of the Sunday broadcast, initially. The launch partner for this flight is New York City's well-known Benjamin Moore banner, Janovic Paint & Decorating Centers. The centers are widely considered to be a preferred destination for discerning New Yorkers, their contractors and designers. http://www.janovic.com
Commencement of Winning Brands' TV advertising in New York City is a significant development for the company as Winning Colours Stain Remover develops the reputation of becoming a favourite amongst consumers who discover it. "Winning Brands is proud to partner with the renowned Benjamin Moore banner in New York to introduce Winning Colours Stain Remover to the city," says Lorne Kelly, Snr. VP of Winning Brands. "It's a big step toward becoming North America's favourite stain removing product -- these fine stores would not carry Winning Colours Stain Remover if it wasn't a terrific product. New Yorkers and their contractors will find a ton of uses for it," he concludes.
Winning Brands CEO Eric Lehner points out that the value of the company's brands is related to public awareness of them -- and that this is growing. "It's how we build value for Winning Brands shareholders," states Lehner; "The HGTV audience is particularly loyal to programs involving the home. By adding HGTV to the media mix we are strengthening our ability to reach the right viewers and attentive audiences. That's what our business plan is about, pure and simple -- identify markets, put superior distribution and retailing partnerships into place, commence advertising and experience growth. Things are progressing in a systematic manner -- well, I guess you could say that the commencement of business on this scale in the Big Apple is more than merely systematic. It means that we have truly arrived."
Winning Brands Corporation manufactures Winning Colours(R) Stain Remover for consumer and commercial use as an eco-responsible alternative to traditional solvents. Production takes place at the Grand Rapids, Michigan facility of Surefil LLC. Winning Brands' full product range includes a variety of environmentally preferable alternative cleaning solutions, such as its non-toxic SMART(TM) Wet Cleaning Solutions alternative to Perchloroethylene used in Dry Cleaning, KIND(TM) Laundry Products and CLEAN1(TM) -- the first choice in outdoor cleaning. The company's mission is to replace hazardous chemicals in widespread use with safer alternatives. The initial focus is on cleaning products.
Certain statements in this news release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Winning Brands Corporation (the Company) to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; and (iii) competitive factors and developments beyond the Company's control. Winning Colors(R), Winning Colours(R) is a Registered Trademark of Niagara Mist Marketing Ltd . KIND(TM) and CLEAN1(TM) are trademarks of Niagara Mist Marketing Ltd. SMART(TM) is a trademark of Solvent Free Solutions Inc.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=717620
Information: Winning Brands Corporation Office Direct (705) 737-4062 11 Victoria Street, Suite 220A Barrie, Ontario, Canada L4N 6T3 News@WinningBrands.ca
SOURCE: Winning Brands Corporation
mailto:News@WinningBrands.ca
Actually Extra, that may be EXACTLY what Eric is hinting at from this 2/24/08 memo. Also, isn't it illegal to bash a stock if you've self proclaimed yourself as short? Save your energy, you're not fooling anyone who's done any DD.
From Eric:
"Thank you for your kind thoughts – and for the opportunity of answering your question. The transition from Non-Reporting Issuer to Reporting Issuer has an intermediate step of Non-Reporting Issuer with Voluntary Disclosure. It is possible that this will be our progression. I have been careful not to provide specific dates for these possible transitions because it is in the company’s culture to do what it says it will do. Until there is certainty about that issue, we consider it more honest to leave this in the category of under review."
Just saw this quote on another board, worth a post here. albeit off topic to some extent...
"The stock market is a wonderfully efficient mechanism for
transferring wealth from the impatient to the patient."
Warren Buffet
bid UT
SAN DIEGO, Mar 19, 2008 (BUSINESS WIRE) -- Aethlon Medical, Inc., (OTCBB:AEMD) today disclosed that it has appointed Cynthia A. Bond to the new position of Director of Investor Relations.
Bond, who will be responsible primarily for Aethlon's investor relations program, brings over 20 years of investor relations and corporate communications experience to the company. During her career, she has represented and counseled companies in a wide range of industry sectors, as well as worked with companies from emerging growth status to large multi-nationals. Her earlier experience as a securities analyst provides valuable background in understanding the needs of professional investors.
"As we transition beyond the research and development phase of our lead Hemopurifier(R) technology, it is appropriate that we broaden the scope of our plans to introduce and educate the financial community on our opportunities in both the infectious disease and cancer marketplace," stated James A. Joyce, Chairman and CEO of Aethlon Medical. "By bringing Cynthia on board we want to emphasize our commitment to shareholders, current and future, and my enthusiasm for the future of Aethlon Medical."
Bond is a graduate of Northwestern University's Kellogg School of Management and holds a B.A. in economics from Connecticut College in New London, Connecticut. Though a Chicago native, she spent several years in New York City before relocating to San Diego.
About Aethlon Medical
Aethlon Medical is the developer of the Hemopurifier(R), a first-in-class medical device designed to treat infectious disease. The Hemopurifier(R) provides real-time therapeutic filtration of infectious viruses and immunosuppressive particles, and is positioned to address the treatment of drug and vaccine resistant viruses. The device also holds promise in cancer care, as research studies have verified the Hemopurifier(R) able to capture immunosuppressive particles that are secreted by tumors. The Hemopurifier(R) is targeted for use a stand-alone therapeutic, and as an adjunct treatment to enhance clinical benefit of established and candidate therapies. Pre-clinical studies conducted by researchers representing leading government and non-government health organizations both in the United States and abroad have documented the effectiveness of the Hemopurifier(R) in capturing pandemic threats, including H5N1 Avian Influenza (bird flu), and Dengue Hemorrhagic Fever (DHF) from circulation. Studies are also being conducted to support the use of the Hemopurifier(R) as a broad-spectrum treatment countermeasure against bioterror threats, including Smallpox, and Ebola, Marburg, and Lassa hemorrhagic fever. Regulatory and commercialization initiatives in the United States are presently focused on bioterror threats, while international initiatives are directed toward naturally evolving pandemic threats, and chronic infectious disease conditions including the Human Immunodeficiency Virus (HIV) and Hepatitis-C (HCV). Aethlon has previously demonstrated safety of the Hemopurifier(R) in a 24-treatment human study at the Apollo Hospital in Delhi, India, and is currently conducting further human studies at the Fortis Hospital, also located in Delhi. The Company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) related to advancing the Hemopurifier(R) as a broad-spectrum treatment countermeasure against category "A" bioterror threats. Additional information regarding Aethlon Medical and its Hemopurifier(R) technology is available online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
SOURCE: Aethlon Medical, Inc.
Aethlon Medical, Inc.
Cynthia Bond
Director of Investor Relations
858-735-0069
cbond@aethlonmedical.com
or
Jeff Richardson
Senior Director, Communications
858-459-7800 ext. 302
jrichardson@aethlonmedical.com
Let's not read too much into that comment (although it's hard not to)... I don't want to be the reason should we lose any kind of negotiation rights. Let's just pretend we didn't read that for now :)